These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 21750962)

  • 21. Genetic testing for RAD51C mutations: in the clinic and community.
    Sopik V; Akbari MR; Narod SA
    Clin Genet; 2015 Oct; 88(4):303-12. PubMed ID: 25470109
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Screening for RAD51 and BRCA2 BRC repeat mutations in breast and ovarian cancer families.
    Rapakko K; Heikkinen K; Karppinen SM; Winqvist R
    Cancer Lett; 2006 May; 236(1):142-7. PubMed ID: 16005565
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A HRM-based screening method detects RAD51C germ-line deleterious mutations in Spanish breast and ovarian cancer families.
    Romero A; Pérez-Segura P; Tosar A; García-Saenz JA; Díaz-Rubio E; Caldés T; de la Hoya M
    Breast Cancer Res Treat; 2011 Oct; 129(3):939-46. PubMed ID: 21537932
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A recurrent mutation in PALB2 in Finnish cancer families.
    Erkko H; Xia B; Nikkilä J; Schleutker J; Syrjäkoski K; Mannermaa A; Kallioniemi A; Pylkäs K; Karppinen SM; Rapakko K; Miron A; Sheng Q; Li G; Mattila H; Bell DW; Haber DA; Grip M; Reiman M; Jukkola-Vuorinen A; Mustonen A; Kere J; Aaltonen LA; Kosma VM; Kataja V; Soini Y; Drapkin RI; Livingston DM; Winqvist R
    Nature; 2007 Mar; 446(7133):316-9. PubMed ID: 17287723
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of a common polymorphism in the TopBP1 gene associated with hereditary susceptibility to breast and ovarian cancer.
    Karppinen SM; Erkko H; Reini K; Pospiech H; Heikkinen K; Rapakko K; Syväoja JE; Winqvist R
    Eur J Cancer; 2006 Oct; 42(15):2647-52. PubMed ID: 16930991
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutation analysis of BRIP1/BACH1 in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives.
    Cao AY; Huang J; Hu Z; Li WF; Ma ZL; Tang LL; Zhang B; Su FX; Zhou J; Di GH; Shen KW; Wu J; Lu JS; Luo JM; Yuan WT; Shen ZZ; Huang W; Shao ZM
    Breast Cancer Res Treat; 2009 May; 115(1):51-5. PubMed ID: 18483852
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene.
    Meindl A; Hellebrand H; Wiek C; Erven V; Wappenschmidt B; Niederacher D; Freund M; Lichtner P; Hartmann L; Schaal H; Ramser J; Honisch E; Kubisch C; Wichmann HE; Kast K; Deissler H; Engel C; Müller-Myhsok B; Neveling K; Kiechle M; Mathew CG; Schindler D; Schmutzler RK; Hanenberg H
    Nat Genet; 2010 May; 42(5):410-4. PubMed ID: 20400964
    [TBL] [Abstract][Full Text] [Related]  

  • 28. German family study on hereditary breast and/or ovarian cancer: germline mutation analysis of the BRCA1 gene.
    Hamann U; Brauch H; Garvin AM; Bastert G; Scott RJ
    Genes Chromosomes Cancer; 1997 Feb; 18(2):126-32. PubMed ID: 9115962
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Single nucleotide polymorphisms in noncoding regions of Rad51C do not change the risk of unselected breast cancer but they modulate the level of oxidative stress and the DNA damage characteristics: a case-control study.
    Gresner P; Gromadzinska J; Jablonska E; Stepnik M; Zambrano Quispe O; Twardowska E; Wasowicz W
    PLoS One; 2014; 9(10):e110696. PubMed ID: 25343521
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PALB2 analysis in BRCA2-like families.
    Adank MA; van Mil SE; Gille JJ; Waisfisz Q; Meijers-Heijboer H
    Breast Cancer Res Treat; 2011 Jun; 127(2):357-62. PubMed ID: 20582465
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined Tumor Sequencing and Case-Control Analyses of RAD51C in Breast Cancer.
    Li N; McInerny S; Zethoven M; Cheasley D; Lim BWX; Rowley SM; Devereux L; Grewal N; Ahmadloo S; Byrne D; Lee JEA; Li J; Fox SB; John T; Antill Y; Gorringe KL; James PA; Campbell IG
    J Natl Cancer Inst; 2019 Dec; 111(12):1332-1338. PubMed ID: 30949688
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Screening for genomic rearrangements in BRCA1 and BRCA2 genes in Czech high-risk breast/ovarian cancer patients: high proportion of population specific alterations in BRCA1 gene.
    Ticha I; Kleibl Z; Stribrna J; Kotlas J; Zimovjanova M; Mateju M; Zikan M; Pohlreich P
    Breast Cancer Res Treat; 2010 Nov; 124(2):337-47. PubMed ID: 20135348
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Screening for a BRCA2 rearrangement in high-risk breast/ovarian cancer families: evidence for a founder effect and analysis of the associated phenotypes.
    Machado PM; Brandão RD; Cavaco BM; Eugénio J; Bento S; Nave M; Rodrigues P; Fernandes A; Vaz F
    J Clin Oncol; 2007 May; 25(15):2027-34. PubMed ID: 17513806
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BRCA1 genetic testing in 106 breast and ovarian cancer families from Southern Italy (Sicily): a mutation analyses.
    Russo A; Calò V; Agnese V; Bruno L; Corsale S; Augello C; Gargano G; Barbera F; Cascio S; Intrivici C; Rinaldi G; Gulotta G; Macaluso M; Surmacz E; Giordano A; Gebbia N; Bazan V
    Breast Cancer Res Treat; 2007 Nov; 105(3):267-76. PubMed ID: 17221156
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of rare MSH6 variants with familial breast cancer.
    Wasielewski M; Riaz M; Vermeulen J; van den Ouweland A; Labrijn-Marks I; Olmer R; van der Spaa L; Klijn JG; Meijers-Heijboer H; Dooijes D; Schutte M
    Breast Cancer Res Treat; 2010 Sep; 123(2):315-20. PubMed ID: 19924528
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Frequency of the ATM IVS10-6T-->G variant in Australian multiple-case breast cancer families.
    Lindeman GJ; Hiew M; Visvader JE; Leary J; Field M; Gaff CL; Gardner RJ; Trainor K; Cheetham G; Suthers G; Kirk J
    Breast Cancer Res; 2004; 6(4):R401-7. PubMed ID: 15217508
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High frequency and allele-specific differences of BRCA1 founder mutations in breast cancer and ovarian cancer patients from Belarus.
    Bogdanova NV; Antonenkova NN; Rogov YI; Karstens JH; Hillemanns P; Dörk T
    Clin Genet; 2010 Oct; 78(4):364-72. PubMed ID: 20569256
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The limited spectrum of pathogenic BRCA1 and BRCA2 mutations in the French Canadian breast and breast-ovarian cancer families, a founder population of Quebec, Canada].
    Tonin PN
    Bull Cancer; 2006 Sep; 93(9):841-6. PubMed ID: 16980226
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.